Literature DB >> 1657363

DNA analysis of ductal carcinoma in situ of the breast. A comparison with histologic features.

J L Killeen1, H Namiki.   

Abstract

In 56 cases of ductal carcinoma in situ (DCIS) of the breast, DNA was analyzed by flow cytometry. The results were compared with standard nuclear grading, the degree of necrosis, and tumor size. Twenty-three cases (41%) showed aneuploidy. The degree of nuclear atypia was correlated significantly with aneuploidy. Tumors with low-grade, intermediate-grade, and high-grade nuclear features were aneuploid in 24%, 41%, and 69% of cases, respectively. The degree of necrosis also correlated with nuclear grade but did not correlate with ploidy status. The combined features of nuclear atypia with necrosis did not predict aneuploidy as well as nuclear grade alone. Tumor size did not correlate with ploidy. These findings indicated that nuclear grade was the best histologic predictor of aneuploidy in DCIS. The potential value of this information in treating DCIS is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657363     DOI: 10.1002/1097-0142(19911215)68:12<2602::aid-cncr2820681214>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Cytological and architectural heterogeneity in ductal carcinoma in situ of the breast.

Authors:  C M Quinn; J L Ostrowski
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

Review 2.  Immunohistochemical studies of early breast cancer evolution.

Authors:  D C Allred; P O'Connell; S A Fuqua; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

3.  Prevalence of aneuploidy, overexpressed ER, and overexpressed EGFR in random breast aspirates of women at high and low risk for breast cancer.

Authors:  C J Fabian; C Zalles; S Kamel; B F Kimler; R McKittrick; A S Tranin; S Zeiger; W P Moore; R S Hassanein; C Simon
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.